Quarterly Activities Report and Appendix 4C

• Non-renounceable entitlement offer raised $2.2 million to progress HMBD-002 program
• HMBD-002 abstracts accepted at premier international scientific conferences
• Manufacture of new batch of drug substance initiated by Hummingbird Bioscience

Percheron Therapeutics Limited, an international biotechnology company focused on the development of novel therapies for oncology and rare diseases, provided an update on the Company's continuing progress during the quarter ended 31 March 2026. The Company announced a non-renounceable entitlement offer to eligible shareholders, which raised approximately $2.2 million before associated costs. The funds will be used to progress the development of HMBD-002, which the Company plans to take into a phase II clinical trial in the second half of 2026, and for working capital purposes. The Company also had abstracts accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting and the American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing data from the recently completed phase I study of HMBD-002 and preclinical research conducted in collaboration with QIMR Berghofer. Additionally, Percheron's licensor, Hummingbird Bioscience, initiated manufacture of a new batch of drug substance for use in upcoming clinical trials, as per the terms of the license agreement signed in 2025.